{"filing":{"accession_number":"0001193125-26-270280","cik":"0001520262","ticker":"ALKS","company_name":"Alkermes plc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"alks-20260615.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1520262/000119312526270280/alks-20260615.htm"},"events":[{"id":10890,"run_id":9553,"accession_number":"0001193125-26-270280","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Alkermes announced the grant of orphan drug designations by the FDA and European Commission for alixorexton in idiopathic hypersomnia and narcolepsy indications, providing significant regulatory and commercial benefits including extended market exclusivity, tax credits, and reduced approval timelines.","company_name":"Alkermes plc.","ticker":"ALKS","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7320,"accession_number":"0001193125-26-270280","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Alkermes announced the grant of orphan drug designations to alixorexton, a regulatory milestone that provides significant commercial and development advantages (extended exclusivity, tax credits, fee waivers). While this is a positive regulatory event, it does not fit neatly into the standard 8-K taxonomy categories (not earnings, M\u0026A, executive changes, impairment, litigation, or cybersecurity). The orphan drug designation is material to investors assessing the company's pipeline and competitive position, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T11:11:08.398818+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7321,"accession_number":"0001193125-26-270280","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA and European Commission orphan drug designations for alixorexton in two rare disease indications (idiopathic hypersomnia and narcolepsy). Orphan drug status provides significant regulatory and commercial benefits including market exclusivity, tax credits, and reduced approval timelines—material to a biopharmaceutical company's pipeline value and investor assessment. This does not fit the more specific event categories but clearly affects the total mix of information about the registrant's development prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T11:11:08.398818+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7320,"accession_number":"0001193125-26-270280","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Alkermes announced the grant of orphan drug designations to alixorexton, a regulatory milestone that provides significant commercial and development advantages (extended exclusivity, tax credits, fee waivers). While this is a positive regulatory event, it does not fit neatly into the standard 8-K taxonomy categories (not earnings, M\u0026A, executive changes, impairment, litigation, or cybersecurity). The orphan drug designation is material to investors assessing the company's pipeline and competitive position, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T11:11:08.398818+00:00","company_name":"Alkermes plc.","ticker":"ALKS","filing_date":"2026-06-15"},{"id":7321,"accession_number":"0001193125-26-270280","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA and European Commission orphan drug designations for alixorexton in two rare disease indications (idiopathic hypersomnia and narcolepsy). Orphan drug status provides significant regulatory and commercial benefits including market exclusivity, tax credits, and reduced approval timelines—material to a biopharmaceutical company's pipeline value and investor assessment. This does not fit the more specific event categories but clearly affects the total mix of information about the registrant's development prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T11:11:08.398818+00:00","company_name":"Alkermes plc.","ticker":"ALKS","filing_date":"2026-06-15"}]}